Minor Steroidal Alkaloids from the Marine Sponge *Corticium* sp.[#]

Nicola Borbone,[†] Simona De Marino,[†] Maria Iorizzi,[‡] Franco Zollo,[*,†] Cecile Debitus,[§] Giuseppe Esposito,[⊥] and Teresa Iuvone[⊥]

Dipartimento di Chimica delle Sostanze Naturali, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49 80131 Napoli, Italy, Dipartimento di Scienze e Tecnologie Agro-Alimentari, Ambientali e Microbiologiche, Università degli Studi del Molise, Via F. De Sanctis, 86100 Campobasso, Italy, IRD, Centre de Nouméa, BPA5, 98848 Nouméa Cedex, New Caledonia, and Dipartimento di Farmacologia Sperimentale, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49 80131 Napoli, Italy

Received January 25, 2002

Four new steroidal alkaloids, plakinamine G (**1**), plakinamine H (**2**), 4α-hydroxydemethylplakinamine B (**3**), and tetrahydroplakinamine A (**4**), along with three known compounds, were isolated from the marine sponge *Corticium* sp. The structures of these metabolites were elucidated largely by 1D and 2D NMR methods and accurate mass measurements (HR-EIMS). Compounds **1**, **2**, and **4** show significant in vitro cytotoxicity.

Among marine organisms sponges are renowned for their ability to produce novel natural products with unique structures and biological activities.[1−3] These invertebrates contain a vast array of polyketides, terpenes, alkaloids, pigments, and cyclic peptides[4] but only a few steroidal alkaloids.[5−9] During our investigation of bioactive compounds from marine organisms, we previously reported the structural elucidation of seven steroidal alkaloids from a sample of *Corticium* sp. collected off Porth Havannah, Vanuatu, South Pacific.[7,8] A second collection of *Corticium* sp. contained a different array of metabolites that included the known steroidal alkaloids *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B, 24,25-dihydroplakinamine A, and *N*-methyltetrahydroplakinamine A.[8] Four new steroidal alkaloids, plakinamines G−H (**1**, **2**), 4α-hydroxydemethylplakinamine B (**3**), and tetrahydroplakinamine A (**4**), were isolated.

The freeze-dried sponge was extracted with methanol, and the methanolic extract was subjected to a modified Kupchan's partitioning procedure.[10] The $CHCl_3$- and BuOH-soluble materials were fractionated by droplet countercurrent chromatography (DCCC) and purified by HPLC to give pure plakinamines G (**1**) and H (**2**), 4α-hydroxydemethylplakinamine B (**3**), and tetrahydroplakinamine A (**4**), along with the known *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B,[8] 24,25-dihydroplakinamine A,[8] and *N*-methyltetrahydroplakinamine A.[8] The structures of these metabolites were determined by interpretation of the 1D and 2D NMR (^{1}H, ^{13}C, DEPT, COSY, TOCSY, HMQC, HMBC, and ROESY) spectra, UV, and accurate mass measurements (HR-EIMS).



Plakinamine G (**1**) corresponded to $C_{29}H_{44}N_2O$ on the basis of its combined HR-EIMS *m*/*z* 436.3458 (calcd 436.3454) and ^{13}C NMR spectral features. Analysis of its ^{1}H NMR, ^{13}C NMR, and COSY spectra (Table 1) revealed the tetracyclic system of **1** to be identical to that of 24,25-dihydroplakinamine A.[8] The main difference observed was in the substitution pattern of the side chain. The UV spectrum showed maximal absorption at 276 nm (log ϵ 4.11). The ^{13}C NMR spectrum showed seven low-field signals; among them, those due to one amide carbonyl (δ_C 174.5), one enamine (δ_C 137.1 and 122.3), and one trisubstituted olefin (δ_C 162.1 and 117.8) indicated the presence in the side chain of an α,β-unsaturated γ-lactam ring. Further confirmation of this structural assignment was obtained by an HMBC experiment (Table 2). The two methyl signals at δ_H 1.22 and 1.20 correlate to the tertiary

[#] Dedicated to the memory of Prof. Guido Sodano.

[*] To whom correspondence should be addressed. Tel: + 39-081/678-528. Fax: + 39-081/678-552 E-mail: fzollo@cds.unina.it.

[†] Dipartimento di Chimica delle Sostanze Naturali, Università degli Studi di Napoli "Federico II".

[‡] Università degli Studi del Molise.

[§] IRD, Centre de Nouméa.

[⊥] Dipartimento di Farmacologia Sperimentale, Università degli Studi di Napoli "Federico II".

10.1021/np020027r CCC: $22.00 © 2002 American Chemical Society and American Society of Pharmacognosy
Published on Web 07/10/2002

Table 1. ^{1}H and ^{13}C NMR Chemical Shift Data of Compounds **1**−**3** (CD_3OD)[a]

	1			**2**			**3**		
position	δ_H[b]	δ_C	mult[c]	δ_H[b]	δ_C	mult[c]	δ_H[b]	δ_C	mult[c]
1	1.63, 1.38	32.8	CH_2	2.09, 1.71	38.0	CH_2	1.59, 1.34	32.1	CH_2
2	1.73, 1.30	30.6	CH_2	1.87	22.5	CH_2	1.85, 1.76	25.5	CH_2
3	3.25 br s	47.6	CH		72.2	CH	3.20 br s	53.0	CH
4	1.66, 1.45	35.1	CH_2		211.8	C	3.60 dd (11.0, 4.0)	71.5	CH
5	1.65	35.6	CH	2.38 dd (11.2, 4.3)	55.3	CH	1.48	42.5	CH
6	1.73	30.3	CH_2	2.17, 1.89	26.0	CH_2	2.27	26.3	CH_2
7	5.22	118.8	CH	5.22 br s	117.5	CH	5.25 br d (3.7)	118.5	CH
8		140.4	C		139.7	C		140.2	C
9	1.83	50.7	CH	2.06	50.7	CH	1.85	50.6	CH
10		35.9	C		42.6	C		37.0	C
11	1.65, 1.51	22.3	CH_2	1.71, 1.56	23.2	CH_2	1.66, 1.52	22.3	CH_2
12	2.08 br d (11.4), 1.35	40.7	CH_2	1.75, 2.07	40.6	CH_2	2.05 br d (12.8), 1.30	40.7	CH_2
13		44.4	C		44.6	C		44.5	C
14	1.90	56.0	CH	1.89	56.2	CH	1.88	56.3	CH
15	1.57, 1.45	23.9	CH_2	1.54, 1.46	23.9	CH_2	1.47	23.9	CH_2
16	1.87, 1.58	28.5	CH_2	1.72	29.1	CH_2	1.70	29.1	CH_2
17	1.50	57.7	CH	1.36	57.3	CH	1.34	57.3	CH
18	0.66 s	12.3	CH_3	0.59 s	12.6	CH_3	0.60 s	12.2	CH_3
19	0.83 s	12.7	CH_3	0.72 s	15.3	CH_3	0.87 s	14.2	CH_3
20	2.68 m	36.7	CH	2.18 m	42.4	CH	2.17 m	42.4	CH
21	1.13 d (6.6)	20.9	CH_3	1.07 d (6.6)	21.5	CH_3	1.07 d (6.6)	21.5	CH_3
22	5.36 d (10.7)	122.3	CH	5.49 dd (15.5, 9.0)	136.0	CH	5.48 dd (15.8, 8.8)	136.2	CH
23		137.1	C	6.40 d (15.5)	126.3	CH	6.39 d (15.8)	126.0	CH
24		162.1	C		127.7	C		127.2	C
25	2.85 m	26.6	CH		128.4	C		128.0	C
26	1.20 d[d]	24.0	CH_3	3.31	50.2	CH_2	2.91 s	60.8	CH_2
27	1.22 d[e]	22.8	CH_3	1.73 s	16.3	CH_3	1.73 s	16.4	CH_3
28	5.82 s	117.8	CH	2.22	25.8	CH_2	2.28 br t	27.0	CH_2
29		174.5	C	2.99 t (5.9)	43.6	CH_2	2.58 t (5.9)	53.2	CH_2
$N(CH_3)_2$				2.35 s	42.1	CH_3	2.33 s	45.5	CH_3

[a] The assignments were based on the COSY, TOCSY, HMQC, and HMBC experiments. [b] Coupling constants (in Hz) are given in parentheses. [c] Multiplicities were assigned from DEPT spectra. [d] Overlapped with CH_3-27. [e] Overlapped with CH_3-26.

Table 2. HMBC[a] Correlations of the Side Chain in Compounds **1** and **2**

1			**2**		
δ_H	δ_C ($^2J_{HC}$)	δ_C ($^3J_{HC}$)	δ_H	δ_C ($^2J_{HC}$)	δ_C ($^3J_{HC}$)
H-21 (1.13)	C-20 (36.7)	C-17 (57.7) C-22 (122.3)	$N(CH_3)_2$ (2.35)		$N(CH_3)_2$ (42.1) C-3 (72.2)
H-26 (1.20)	C-25 (26.6)	C-24 (162.1) C-27 (22.8)	H-26 (3.31)	C-25 (128.4)	C-24 (127.7) C-29 (43.6)
H-27 (1.22)	C-25 (26.6)	C-24 (162.1) C-26 (24.0)	H-29 (2.99)		C-24 (127.7) C-26 (50.2)
H-28 (5.82)	C-24 (162.1) C-29 (174.5)	C-23 (137.1)			

[a] HMBC optimized for $^{2,3}J_{CH}$ = 10 Hz.

carbon at δ_C 26.6 and to the quaternary carbon at δ_C 162.1, which required their placement in an isopropyl group linked to C-24. The C-21 methyl protons revealed ^2J coupling to C-20 and ^3J coupling to C-17 and C-22. The C-28 olefinic proton at δ_H 5.82 showed ^3J correlation to C-23 at δ_C 137.1 and ^2J correlations to C-24 and C-29 at δ_C 162.1 and 174.5, respectively, which revealed the connection between the γ-lactam and the tetracyclic nucleus.

The molecular formula, $C_{31}H_{48}N_2O$, of plakinamine H (**2**) was established by HR-EIMS *m/z* 464.3760 (calcd 464.3767). The ^{1}H and ^{13}C NMR spectra of **2** were similar to those of *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B[8] (Table 1) except for the disappearance of an *N*-methyl signal. In the HMBC spectrum (Table 2) two *N*-methyl signals at δ_H 2.35 showed ^3J correlations to each other and to C-3 at δ_C 72.2. The upfield ^{13}C NMR shifts of C-29 and C-26 (about 10 ppm compared to *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B) confirmed the absence of the *N*-methyl group in the side chain and allowed the structural elucidation of **2**.

HR-EIMS data (*m/z* 452.3758, calcd 452.3767) of compound **3** revealed the molecular formula $C_{30}H_{48}N_2O$. The ^{1}H and ^{13}C NMR data of **3** (Table 1) were superimposable on those of *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B[8] for C-22 to $-NCH_3$, but significantly different for the tetracyclic nucleus. The ^{13}C NMR spectrum featured a signal at δ_C 53.0, suggesting the presence of the α-amino group at C-3,[11] and a signal at δ_C 71.5 attributable to a hydroxyl group. This was subsequently located at C-4 by HMBC and COSY experiments. Its equatorial conformation was compatible with the chemical shift of CH_3-19 (δ_H 0.87).

The stereochemistry was confirmed by the small $H_{3,4}$ coupling constant (J = 4.0 Hz) and a ROESY experiment which showed correlation of H-4 to CH_3-19 (Figure 1). The low-field signals at δ_C 140.2 and 118.5 were assigned to a Δ^7 double bond, in close analogy with plakinamine G (**1**). Hence compound **3** is *N*-demethyl-4α-hydroxyplakinamine B.

Steroidal alkaloid **4** had the molecular formula $C_{29}H_{50}N_2$, as determined on the basis of ^{13}C NMR data and from its HR-EIMS spectrum, which showed a molecular ion peak at *m/z* 426.3980 (calcd 426.3974). The structure of **4** was readily established by comparison of the ^{1}H NMR, ^{13}C NMR, and COSY spectral data with those of 24,25-dihydroplakinamine A.[8] The chemical shifts of carbon



Figure 1. ROE correlations observed in the steroidal nucleus of **3**.

Table 3. IC_{50} (μg/mL) of Compounds **1**, **2**, **3**, and **4**

compound	C6[a]	RAW 264[b]
1	6.8	nc[c]
2	9.0	61.0
3	26.1	16.2
4	1.4	nc

[a] Rat glioma cell line. [b] Murine macrophage cell line. [c] Not cytotoxic.

atoms 1 to 19 are virtually identical in both compounds (see Experimental Section). The main difference observed in **4** is the replacement in the ^{13}C NMR spectrum of the imine signal of 24,25-dihydroplakinamine A by a carbon signal at δ_C 61.5. Interpretation of the COSY spectrum confirmed the presence of a spin system from C-20 to C-29, indicative of a saturated pyrrolidine ring. On this basis, the structure of **4** was established as tetrahydroplakinamine A.

Cytotoxicity was evaluated on rat glioma (C6) and murine monocyte/macrophages (RAW 264) cell lines (Table 3). Compounds **1** and **4** were the most active against C6 cells (IC_{50}'s 6.8 and 1.4 μg/mL, respectively), whereas they were without effect on RAW 264. Compounds **2** and **3** were cytotoxic against both cell lines, with compound **2** being more active against C6 cells (IC_{50} 9.0 μg/mL) than to RAW 264 (IC_{50} 61 μg/mL), while compound **3** exhibited higher cytotoxicity on RAW 264 (IC_{50} 16.2 μg/mL) than to C6 cells (IC_{50} 26.1 μg/mL).

Experimental Section

General Experimental Procedures. Specific rotations were measured on a Perkin-Elmer 243 B polarimeter. UV spectra were recorded on a Beckman DU-70 spectrophotometer. MS spectra were recorded on a Fisons VG Prospect spectrometer. NMR spectra were recorded on a Bruker AMX-500 spectrometer equipped with a Bruker X32 computer, using the UXNMR software package. ^{1}H and ^{13}C NMR spectra were recorded at 500.13 and 125.76 MHz, respectively. Chemical shifts are referenced to residual CHD_2OD (3.31 ppm) in CD_3OD; ^{13}C chemical shifts are referenced to the solvent (CD_3OD, 49.0 ppm).

Animal Material. Samples of the sponge *Corticium* sp. were collected at a depth of 12−18 m at Efatè, Porth Havannah, Vanuatu, South Pacific, in July 1996. The samples were frozen immediately after collection and lyophilized to yield 550 g of dry mass. The sponge was identified by Dr. John Hooper of the Queensland Museum, Brisbane, Australia, as *Corticium* sp. (Homosclerophorida, Plakinidae). A voucher specimen (R1718) has been deposited at the IRD Center in Nouméa, New Caledonia.

Extraction and Isolation. The lyophilized sponge (550 g) was extracted by blending with MeOH (3 × 2 L) at room temperature. The combined extracts (88 g) were concentrated and subjected to a modified Kupchan's partition as follows. The MeOH extract was dissolved in 10% aqueous methanol and partitioned against *n*-hexane. The water content (% v/v) of the MeOH extract was adjusted to 20% and 40% and partitioned against CCl_4 and $CHCl_3$ respectively, yielding 4.9 g of $CHCl_3$ extract. The aqueous phase was concentrated to remove MeOH and then extracted with *n*-BuOH. The $CHCl_3$ extract (1.2 g) was fractionated by DCCC using $CHCl_3$/MeOH/H_2O (7:13:8) in the ascending mode (the lower phase was the stationary phase). Fractions (6 mL each) were collected and examined by TLC on SiO_2 with $CHCl_3$/MeOH/H_2O (80:18:2) as eluent. Fractions 9−16 were pooled and purified by HPLC on a C_{18} μ-Bondapak column (30 cm × 3.9 mm i.d.) eluting with MeOH/H_2O/TEA (95:5:0.5) to yield pure compound **2** (3.4 mg), pure *N,N*-dimethyl-4-oxo-3-*epi*-plakinamine B[8] (6.3 mg), and pure *N*-methyltetrahydroplakinamine A[8] (19.8 mg). Fractions 28−32 were purified by HPLC on a C_{18} μ-Bondapak column (30 cm × 3.9 mm i.d.) with MeOH/H_2O/TEA (93:7:0.5) as eluent to yield pure compound **1** (1.1 mg), while fractions 38−78 under the same conditions gave pure 24,25-dihydroplakinamine A[8] (2.5 mg). The *n*-BuOH extract (6.6 g) was chromatographed on a Sephadex LH-60 column (3 × 80 cm) and eluted with MeOH/H_2O (2:1). Fractions 108−123 were pooled (1.49 g) and fractionated by DCCC using *n*-BuOH/Me_2CO/H_2O (3:1:5) in the descending mode (the upper phase was used as stationary phase). Fractions (6 mL each) 81−98 and 107−115 were purified by HPLC on a C_{18} μ-Bondapak column (30 cm × 3.9 mm i.d.) eluted with MeOH/H_2O/TEA (95:5:0.5) to give pure compounds **3** (2.4 mg) and **4** (2.5 mg), respectively.

Cytotoxicity Tests. C6 and RAW 264 cells (3.5 × 10^3 cells) were plated on 96-well plates in 50 μL and allowed to adhere at 37 °C in 5% CO_2/air for 2 h. Thereafter, 50 μL of 1:4 (v/v) serial dilution of the test compounds was added and incubated with the cells for 24 h. Cell viability was assessed through an MTT conversion assay.[12] After 24 h, 25 μL of MTT (5 mg/mL) was added, and the cells were incubated for an additional 3 h. After this time, the cells were lysed and the dark blue crystals solubilized with 100 μL of a solution containing 50% (v/v) *N,N*-dimethylformamide and 20% (w/v) SDS with an adjusted pH of 4.5.[13] The optical density (OD) of each well was measured with a microplate spectrophotometer (Titerteck Multiskan MCC/340) equipped with a 620 nm filter. The viability of each cell line was calculated as % dead cells = 100 − (OD treated/OD control) × 100.

Plakinamine G (1): colorless gum; $[\alpha]^{22}_D$ −24.4° (*c* 0.09, MeOH); UV (MeOH) λ_{max} (log ϵ) 276 (4.11); ^{1}H and ^{13}C NMR data (CD_3OD), see Table 1; HREIMS *m*/*z* 436.3458 (calcd for $C_{29}H_{44}N_2O$, 436.3454).

Plakinamine H (2): colorless gum; $[\alpha]^{22}_D$ +29.0° (*c* 0.10, MeOH); UV (MeOH) λ_{max} (log ϵ) 250 (3.77); ^{1}H and ^{13}C NMR data (CD_3OD), see Table 1; HREIMS *m*/*z* 464.3760 (calcd for $C_{31}H_{48}N_2O$, 464.3767).

4α-Hydroxydemethylplakinamine B (3): colorless gum; $[\alpha]^{22}_D$ +6.7° (*c* 0.09, MeOH); UV (MeOH) λ_{max} (log ϵ) 241 (3.80); ^{1}H and ^{13}C NMR data (CD_3OD), see Table 1; HREIMS *m*/*z* 452.3758 (calcd for $C_{30}H_{48}N_2O$, 452.3767).

Tetrahydroplakinamine A (4): colorless gum; $[\alpha]^{22}_D$ +23.2° (*c* 0.19, MeOH); ^{1}H NMR (CD_3OD, 500.13 MHz) δ 5.22 (1H, br s, H-7), 3.25 (1H, br s, H-3), 3.09 (1H, m, H-23), 2.97 (2H, m, H_2-29), 2.09 (1H, br d, J = 12.1 Hz, H-12), 1.96 (1H, H-28), 1.88 (1H, H-14), 1.83 (1H, H-9), 1.81 (1H, H-22), 1.78 (1H, H-24), 1.76 (1H, H-16), 1.73 (1H, H-25), 1.73 (1H, H-2), 1.73 (1H, H-6), 1.69 (1H, H-6), 1.66 (1H, H-4), 1.65 (1H, H-5), 1.65 (1H, H-11), 1.63 (1H, H-1), 1.58 (1H, H-16), 1.57 (1H, H-15), 1.52 (1H, H-20), 1.51 (1H, H-11), 1.48 (1H, H-15), 1.45 (1H, H-4), 1.39 (1H, H-1), 1.31 (1H, H-17), 1.30 (1H, H-2), 1.29 (1H, H-22), 1.29 (1H, H-12), 1.06 (3H, d, J = 6.6 Hz, CH_3-21), 0.99 (3H, d, J = 5.9 Hz, CH_3-26), 0.93 (3H, d, J = 5.9 Hz, CH_3-27), 0.84 (3H, s, CH_3-19), 0.61 (3H, s, CH_3-18); ^{13}C NMR (CD_3OD, 125.76 MHz) δ 140.4 (C-8), 118.8 (C-7), 61.5 (C-23), 57.9 (C-17), 56.0 (C-14), 52.0 (C-24), 50.7 (C-9), 47.6 (C-3), 45.6 (C-29), 44.5 (C-13), 42.1 (C-22), 40.6 (C-12), 35.9 (C-20), 35.9 (C-10), 35.6 (C-5), 35.1 (C-4), 32.8 (C-1), 30.6 (C-2), 30.5 (C-25), 30.3 (C-6), 28.8 (C-16), 27.1 (C-28), 23.7 (C-15), 22.3 (C-11), 21.7 (C-26), 19.4 (C-21), 18.3 (C-27), 12.7 (CH_3-19), 12.3 (CH_3-18); HREIMS *m*/*z* 426.3980 (calcd for $C_{29}H_{50}N_2$, 426.3974).

References and Notes

(1) Fusetani, N.; Matsunaga, S. *Chem. Rev.* **1993**, *93*, 1793−1806.
(2) Ireland, C. M.; Copp, B. R.; Foster, M. P.; McDonald, L. A.; Radisky, D. C.; Swersey, J. C. In *Marine Biotechnology, Pharmaceutical and Bioactive Natural Products*; Attaway, D., Zaborsky, O. R., Eds.; Plenum Publishing Corp.: New York, 1993; Vol. 1, pp 1−43.
(3) Harper, M. K.; Bugni, T. S.; Copp, B. R.; James, R. D.; Lindsay, B. S.; Richardson, A. D.; Schnabel, P. C.; Tasdemir, D.; Vanwagoner, R. M.; Verbitsky, S. M.; Ireland, C. M. In *Marine Chemical Ecology*; McClintock, J. B., Baker, B. J., Eds.; CRC Press LLC: New York, 2001; pp 3−69.
(4) Faulkner, D. J. *Nat. Prod. Rep.* **2001**, *18*, 1−49, and previous reports in this series.
(5) Rosser, M. R.; Faulkner, D. J. *J. Org. Chem.* **1984**, *49*, 5157−5160.
(6) Jurek, J.; Scheuer, P. J.; Kelly-Borges, M. *J. Nat. Prod.* **1994**, *57*, 1004−1007.
(7) De Marino, S.; Zollo, F.; Iorizzi, M.; Debitus, C. *Tetrahedron Lett.* **1998**, *39*, 7611−7614.
(8) De Marino, S.; Iorizzi, M.; Zollo, F.; Roussakis, C.; Debitus, C. *Eur. J. Org. Chem.* **1999**, 697−701.
(9) Lee, H. S.; Seo, Y.; Rho, J. R.; Shin, J.; Paul, V. J. *J. Nat. Prod.* **2001**, *64*, 1474−1476.
(10) Kupchan, S. M.; Britton, R. W.; Ziegler, M. F.; Sigel, C. W. *J. Org. Chem*. **1973**, *38*, 178−179.
(11) Agrawal, P. K.; Srivastava, S. K.; Gaffield, W. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Springer-Verlag: New York, 1991; Vol. 7, p 197.
(12) Mosmann, T. *J. Immunol. Methods* **1983**, *65*, 55−63.
(13) Opipari, A. W., Jr.; Hu, H. M.; Yabkowitz, R.; Dixit, V. M.. *J. Biol. Chem.* **1992**, *267*, 12424−12427.

NP020027R